Melanoma medicine: New drugs for melanoma and the role of the general practitioner

September 11, 2024

Abstract

Background
Following major achievements seen with drug therapies for the treatment of advanced melanoma in the last decade, they now also have an ever-increasing role for the treatment of earlier stage disease. This review outlines the current drugs used to treat melanoma, and how general practitioners (GPs) can assist in the management of patients with melanoma and the associated toxicities with treatment.

Objective
This review summarises the evolving status of melanoma care, emphasising when to refer patients to medical oncologists as part of the multidisciplinary team. It provides guidance into recognising and managing immune-related adverse events (irAEs) associated with immunotherapy, and provides insights into the future changes in clinical practice.

Discussion
Drug therapies are increasingly used for the treatment of many patients with melanoma. Early referral is crucial, and clinical trials remain the best choice for most patients. Recognition and prompt management of irAEs is vital, and collaboration between GPs and oncologists is essential for best care.

Source:

Boutros A, Carlino MS, Menzies AM. Melanoma medicine: New drugs for melanoma and the role of the general practitioner. Aust J Gen Pract. 2024 Sep;53(9):619-624. doi: 10.31128/AJGP-01-24-7129. PMID: 39226594.

https://pubmed.ncbi.nlm.nih.go...